Literature DB >> 20857156

Gender influence on ocular manifestations and their outcome in Behcet's Disease. A long-term follow-up of up to 20 years.

Fereydoun Davatchi1, Farhad Shahram, Hormoz Shams, Abdolhadi Nadji, Cheyda Chams-Davatchi, Massoomeh Akhlaghi, Seyedeh Tahereh Faezi, Farima Ashofteh, Bahar Sadeghi-Abdollahi.   

Abstract

It is of general belief that males are prone to more frequent, more severe manifestations, and less favorable outcome. We evaluated this hypothesis in ophthalmological manifestations (OM) of Behcet's Disease (BD). Visual acuity (VA), anterior uveitis, posterior uveitis (PU), and retinal vasculitis (RV) were checked, according to Ben Ezra, in 1,515 patients with eye lesions. The data at baseline and last visit were compared. Male/female ratio was 1.2 in the BD registry (6,500 patients) and 1.51 for OM patients (Chi(2) = 98.962, p < 0.0001). The patients-year-follow-up was 4,987. All parameters improved significantly from the baseline. Mean VA improved from 4.87 to 5.35 for males (p < 0.0001) and from 5.20 to 5.74 for females (p < 0.0001). Difference between males/females at baseline was not significant (p = 0.60). The mean improvement for males/females was statistically non-significant (p = 0.58). Percent improvement of eyes for males/females was 47.1%/48.8% (p = 0.41). Mean PU improved from 1.83 to 0.71 for males (p < 0.0001) and from 1.66 to 0.49 for females (p < 0.0001). Difference between males/females at baseline was significant (p = 0.01). The mean improvement for males/females was statistically non-significant (p = 0.45). Percent improvement of eyes for males/females was 75.4%/81.0% (p = 0.004). Mean RV improved from 2.05 to 1.16 for males (p < 0.0001) and from 1.97 to 0.99 for females (p < 0.0001). Difference between males/females at baseline was not significant (p = 0.42). The mean improvement for males/females was statistically non-significant (p = 0.47). Percent improvement of eyes for males/females was 62%/64.4% (p = 0.33). Male gender is more prone to ocular manifestations. The severity of lesions at baseline was the same for VA and RV. For PU, the difference was statistically significant, but was not clinically relevant. The therapeutic outcome (mean improvement and percent of improved eyes) was the same for all parameters.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20857156     DOI: 10.1007/s10067-010-1574-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  How to deal with Behcet's disease in daily practice.

Authors:  Fereydoun Davatchi; Farhad Shahram; Cheyda Chams-Davatchi; Hormoz Shams; Abdolhadi Nadji; Massoomeh Akhlaghi; Tahereh Faezi; Bahar Sadeghi Abdollahi
Journal:  Int J Rheum Dis       Date:  2010-05       Impact factor: 2.454

2.  Validation of the International Criteria for Behçet's disease (ICBD) in Iran.

Authors:  Fereydoun Davatchi; Bahar Sadeghi Abdollahi; Farhad Shahram; Abdolhadi Nadji; Cheyda Chams-Davatchi; Hormoz Shams; Nasim Naderi; Massoomeh Akhlaghi; Tahereh Faezi; Alireza Faridar
Journal:  Int J Rheum Dis       Date:  2010-02-01       Impact factor: 2.454

3.  Surgical treatment result of abdominal aortic aneurysm in Behçet's disease.

Authors:  T-W Kwon; S-J Park; H-K Kim; H-K Yoon; G-E Kim; B Yu
Journal:  Eur J Vasc Endovasc Surg       Date:  2007-10-26       Impact factor: 7.069

4.  Behcet's disease in Iran: analysis of 6500 cases.

Authors:  Fereydoun Davatchi; Farhad Shahram; Cheyda Chams-Davatchi; Hormoz Shams; Abdolhadi Nadji; Massoomeh Akhlaghi; Tahereh Faezi; Zahra Ghodsi; Roghieh Larimi; Farima Ashofteh; Bahar Sadeghi Abdollahi
Journal:  Int J Rheum Dis       Date:  2010-10       Impact factor: 2.454

5.  Thrombosis in Behçet's disease: a retrospective survey from a single UK centre.

Authors:  P R Ames; A Steuer; A Pap; A M Denman
Journal:  Rheumatology (Oxford)       Date:  2001-06       Impact factor: 7.580

6.  [Neurological involvement in Behçet's disease. 154 cases from a cohort of 925 patients and review of the literature].

Authors:  S Benamour; T Naji; F-Z Alaoui; H El-Kabli; S El-Aidouni
Journal:  Rev Neurol (Paris)       Date:  2006-11       Impact factor: 2.607

7.  Male patients with Behçet's syndrome have stronger pathergy reactions.

Authors:  H Yazici; Y Tüzün; A B Tanman; S Yurdakul; S Serdaroglu; H Pazarli; A Müftüoglu
Journal:  Clin Exp Rheumatol       Date:  1985 Apr-Jun       Impact factor: 4.473

8.  Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome.

Authors:  H Yazici; Y Tüzün; H Pazarli; S Yurdakul; Y Ozyazgan; H Ozdoğan; S Serdaroğlu; M Ersanli; B Y Ulkü; A U Müftüoğlu
Journal:  Ann Rheum Dis       Date:  1984-12       Impact factor: 19.103

9.  Characteristics of vascular involvement in Behçet's disease.

Authors:  N Düzgün; A Ateş; O T Aydintuğ; O Demir; U Olmez
Journal:  Scand J Rheumatol       Date:  2006 Jan-Feb       Impact factor: 3.641

10.  Clinical features of chinese patients with Behçet's disease.

Authors:  Peizeng Yang; Wang Fang; Qianli Meng; Yalin Ren; Lin Xing; Aize Kijlstra
Journal:  Ophthalmology       Date:  2007-08-10       Impact factor: 12.079

View more
  4 in total

1.  [Update: Behçet's disease].

Authors:  I Kötter
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

Review 2.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

3.  Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis.

Authors:  T C Mitulescu; C Popescu; A Naie; D Predeţeanu; V Popescu; C Alexandrescu; L M Voinea
Journal:  J Med Life       Date:  2015 Jul-Sep

Review 4.  Gender and ocular manifestations of connective tissue diseases and systemic vasculitides.

Authors:  Maria M Choudhary; Rula A Hajj-Ali; Careen Y Lowder
Journal:  J Ophthalmol       Date:  2014-03-17       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.